MedDataX Logo

Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

NCT ID: NCT00206193

Last Updated: 2007-10-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Study Classification

OBSERVATIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abortion, Induced

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

termination of pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mifepristone

Intervention Type DRUG

misoprostol

Intervention Type DRUG

sulprostone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria

* Women with liver/kidney disease
* Women on long-term use of corticosteroids (\> 6 months)
* Cardiovascular problems
* Therapy-resistant diabetic women
* Therapy-resistant asthma/bronchitis
* Thalassemia
* Ulcerative colitis
* Peptic ulcer disease
* Glaucoma
* Porphyria
* Allergic reaction to prostaglandin or mifepristone
* Women with a prior caesarian section or women with contractions at the start of the study
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Atrium Medical Center

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

F Roumen, Dr.

Role: STUDY_DIRECTOR

Atrium Medisch Centrum, Heerlen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Atrium Medisch Centrum

Heerlen, Limburg, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Suzanne HW Vonken, Dr.

Role: CONTACT

Phone: 003145-5766666

Email: [email protected]

F Roumen, Dr.

Role: CONTACT

Phone: 003145-5766666

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Suzanne HW Vonken, Dr.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TOP-protocol

Identifier Type: -

Identifier Source: org_study_id